Homozygous and heterozygous CCR5-Δ32 genotypes are associated with resistance to HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 27, Issue 5, 2001, Pages 472-481

  Marmor, Michael ^a   Sheppard, Haynes W ^b   Donnell, Deborah ^c   Bozeman, Sam ^d   Celum, Connie ^e   Buchbinder, Susan ^f   Koblin, Beryl ^g   Seage III, George R ^d,h  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

^c USA   (United States)

^d ABT ASSOCIATES   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^g NEW YORK BLOOD CENTER   (United States)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

CCR5 32; Epidemiology; Exposed; HIV 1; Resistance; Seronegative; Susceptibility; Transmission; Uninfected

Indexed keywords

CHEMOKINE RECEPTOR CCR5;

ADULT; ARTICLE; FEMALE; GENOTYPE; HETEROZYGOSITY; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION SENSITIVITY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEROCONVERSION; UNITED STATES; VIRUS RESISTANCE;

EID: 0035881173     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200108150-00009     Document Type: Article

References (44)

1. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene
2. Genetic determinants of HIV-1 infection and its manifestations
3. Protection against parenteral HIV-1 infection by homozygous deletion in the C-C chemokine receptor 5 gene
4. A 32-bp deletion within the CCR5 locus protects against transmission of parenterally acquired human immunodeficiency virus but does not affect progression to AIDS-defining illness
5. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene
6. CCR5 genotype and resistance to vertical transmission of HIV-1
7. Possible influence of the mutant CCR5 allele on vertical transmission of HIV-1
8. HIV-1 infection in a man homozygous for CCR5 delta 32
9. HIV-1 infection in an individual homozygous for CCR5 delta 32
10. HIV-1 infection in an individual homozygous for the CCR5 deletion allele
11. Homozygous 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient
12. HIV-1 infection in a heterosexual man homozygous for CCR-5 Δ32
13. An HIV-1 infected individual homozygous for the CCR-5 Δ32 allele and the SDF-1 3′A allele
14. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression
15. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression
16. Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons
17. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
18. Variants of the human NRAMP1 gene and altered human immunodeficiency virus infection susceptibility
19. Distinctive effects of CCR5, CCR2, and SSDF1 genetic polymorphisms in AIDS progression
20. HIV-1-infected long-term slow progressors heterozygous for Delta 32-CCR5 show significantly lower plasma viral load than wild-type slow progressors
21. CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children
22. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals
23. Decreased susceptibility of peripheral blood mononuclear cells from individuals heterozygous for a mutant CCR5 allele to HIV infection
24. Frequency of a mutated CCR-5 allele (Delta 32) among Italian healthy donors and individuals at risk for parenteral HIV infection
25. CCR5 genotype and HIV-1 infection in perinatally-exposed infants
26. CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status
27. Homozygosity for CCR5 deletion (Δ32/Δ32) explains protection from HIV-1 infection in few very high risk HIV-homosexual men
28. Do delta 32 CCR-5 deletions protect intravenous drug users (IDUs) against HIV infection
29. Readiness of high-risk populations in the HIV Network for Prevention Trials (HIVNET) to participate in HIV vaccine efficacy trials in the United States
30. The HIVNET Vaccine Preparedness Study (VPS): Are United States populations appropriate for HIV vaccine trials?
31. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression
32. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression
33. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS)
34. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant
35. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay
36. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas
37. 2 tests with one degree of freedom: Extensions of the Mantel-Haenszel procedure
38. Censored data and the bootstrap
39. Current evidence and future directions for targeting HIV entry: Therapeutic and prophylactic strategies
40. Incidence of the acquired immunodeficiency syndrome in San Francisco 1980-1983
41. Epidemiology of human immunodeficiency virus type 1 infection among homosexual men participating in hepatitis B vaccine trials in Amsterdam, New York City, and San Francisco, 1978-1990